A healthcare provider shares her journey with multiple myeloma, discussing the physical, emotional and financial challenges ...

We are entering an era where "cure," specifically a functional cure, is no longer a forbidden word in the myeloma community.

Each monthly installment examines an aspect of multiple myeloma care, including delivering the diagnosis, building trust, ...

Although patients with the same cancer diagnosis may respond very differently to treatment, clinicians still have limited ...

Once a disease with poor outcomes, multiple myeloma now has new promise thanks to CAR T-cell therapy, which reprograms a patient’s immune cells to attack cancer. Some patients are experiencing ...

CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina ...

Multiple myeloma is a cancer of the bone marrow. And treatment is not a walk in the park.

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.

Bispecific antibodies are currently approved as late-line therapy, but they are moving up to earlier lines “as they prove ...

CAR T-cell therapy is a treatment that uses a patient’s own T cells, genetically reprograms them in a lab to recognize ...

During a live event, Caitlin Costello, MD, discussed the AQUILA trial and its potential impact on treatment for high-risk smoldering myeloma.